09 Nov 2012, BioSpectrum Bureau , BioSpectrum
Mumbai: Continuing with its principle of providing affordable drugs to India and countries across the globe, and its aggressive strategy of producing generics at comparatively low prices, Cipla has reduced the prices of three anti cancer drugs.
Cipla announced a breakthrough price reduction in Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder, colorectal and colon cancers.
There has been a 50 percent price reduction in the case of Capecitabine used in the treatment of metastatic breast cancer, metastatic colorectal cancer, metastatic colon cance from $21.88 (Rs1200)-to-$10.91 (Rs600), as well as Docetaxel prescribed for breast cancer, lung cancer (non-small cell and small cell), head and neck cancer, gastric cancer, bladder cancer which is available in three concentrations , 20mg, 80mg and 120 mg. The price for Erlotinib which is prescribed for lung cancer (metastatic non-small cell cancer) has also been reduced. This step comes close on the heels of Cipla reducing the prices of three other anti cancer drug, namely Sorafenib , Gefitinib and Temozolomide in May.
Commenting on this development, Dr Y K Hamied, CMD, Cipla, said that, "Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and malaria to now include cancer, not only in India but globally."
With a turnover of over $1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. The company has over 34 manufacturing facilities across India, and manufactures more than 2,000 products in 65 therapeutic categories.